Acrivon Therapeutics, Inc. (ACRV)

Insider Trading Filed: 2026-04-21

Chief Legal Officer Mary Miller disposed of 558 shares at $1.78 per share on April 17, 2026, resulting from mandatory tax withholding on vesting restricted stock units rather than a discretionary sale.
Miller retains 33,121 shares of direct beneficial ownership following the transaction, indicating continued material stake in the company despite the stock price at $1.78.
The transaction represents routine equity compensation vesting activity typical for executive officers, with no indication of loss of confidence in the company or strategic shift in insider positioning.

Annual Report Filed: 2026-03-19

Acrivon Therapeutics, Inc. (ACRV) filed its 10-K report for the fiscal year 2025, providing insights into the company's financial performance and operational activities.
The report indicates that Acrivon Therapeutics is focused on the development of its lead drug candidates, ACR368 and ACR2316, as well as its other drug discovery programs.
The company has entered into several key agreements, including the Lilly Agreement and the Akoya Agreement, which may provide additional financial resources and collaborative opportunities.

Current Report Filed: 2026-03-19

Acrivon Therapeutics announced plans to initiate arm 4 of the registrational intent ACR-368 phase 2b study, focusing on serous type endometrial cancer subjects with ≤2 prior lines of therapy. This suggests progress in the company's lead drug candidate development.
The company also completed exploratory arm 2 of the study, which treated biomarker-negative subjects with ≤3 prior lines of therapy using ACR-368 with ultra low dose gemcitabine (ULDG) sensitization. The study objectives were achieved, indicating ULDG may contribute to ACR-368 efficacy in biomarker-negative subjects with a favorable tolerability profile.
The updated corporate presentation provides investors with details on the company's pipeline progress and development strategy, which could be of interest to those tracking Acrivon's advancements.

Insider Trading Filed: 2026-01-21

Insider Mary Miller, the Chief Legal Officer, disposed of 659 shares of Acrivon Therapeutics (ACRV) at $1.98 per share to cover tax withholding requirements on vested restricted stock units.
The reported transaction reduces Miller's direct beneficial ownership to 33,896 shares, indicating she continues to hold a significant stake in the company.
Insider transactions, especially those related to stock awards and tax obligations, can provide insight into management's confidence and alignment with shareholders.

Insider Trading Filed: 2026-01-16

Adam D. Levy, the Chief Financial Officer of Acrivon Therapeutics, Inc. (ACRV), purchased 8,832 shares of the company's common stock on January 14, 2026 at a weighted average price of $1.6983 per share.
The insider purchase represents a direct ownership increase of 72% for Levy, who now beneficially owns a total of 20,983 shares of ACRV.
Insider buying can be a positive signal to investors, as it suggests the CFO's confidence in the company's prospects and potential future appreciation of the stock price.

Insider Trading Filed: 2026-01-16

The reporting person, Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, purchased 49,000 shares of the company's common stock at an average price of $1.676 per share, increasing his direct beneficial ownership to 2,095,771 shares.
Kristina Masson, the EVP of Business Operations and Blume-Jensen's spouse, also holds an indirect beneficial ownership of 314,706 shares of Acrivon Therapeutics.
The Form 4 filing indicates that the insider transactions were made pursuant to a pre-arranged trading plan, suggesting a degree of confidence in the company's long-term prospects.

Insider Trading Filed: 2026-01-15

Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, Inc., has purchased 10,000 shares of the company's common stock at an average price of $1.7218 per share, indicating his confidence in the company's future prospects.
This insider buying activity represents a direct ownership increase of 15.3% for Devroe, suggesting he believes the current stock price presents an attractive investment opportunity.
The transaction was executed through multiple trades within a price range, indicating Devroe's diligence in securing the best possible execution for his purchase.

Current Report Filed: 2026-01-08

Acrivon Therapeutics reported positive interim data from the Phase 2b trial of its CHK1/CHK2 inhibitor ACR-368, showing a 39% ORR in monotherapy for biomarker-positive endometrial cancer patients and a 67% cORR in serous endometrial cancer patients.
The company has submitted a EU Clinical Trial Application to expand the ACR-368 Phase 2b trial into Europe, which is expected to accelerate enrollment and potentially allow for an earlier interim analysis.
Initial clinical data from the ongoing Phase 1 trial of Acrivon's WEE1/PKMYT1 inhibitor ACR-2316 has established favorable tolerability profiles for two weekly oral dosing regimens, providing dosing flexibility for potential future combinations.

Current Report Filed: 2026-01-08

Acrivon Therapeutics, a clinical-stage biopharmaceutical company, provided updates on its lead candidates ACR-368 and ACR-2316, including new clinical data.
The company hosted a corporate webcast and conference call to present the updates, which were also made available on the company's website.
The data update includes information on the progress of Acrivon's pipeline, indicating continued advancement of its programs.

Important Information